Verrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c)

Reports Q4 revenue $344,000, consensus $1.3M. “The fourth quarter began a transition period for our company, and we have already achieved several substantial milestones. We completed our commercial strategy realignment, which generated promising sequential growth of dispensed applicator units of YCANTH while simultaneously implementing significant cost reductions across the organization. We also continued advancing our late-stage clinical programs in basal cell carcinoma and common warts,” said Jayson Rieger, president and CEO of Verrica. Rieger continued “We successfully raised equity capital in the fourth quarter to strengthen our balance sheet and allow us to remain focused on commercial execution and development of our clinical assets.”